Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

por Bocci, G, Fioravanti, A, Orlandi, P, Bernardini, N, Collecchi, P, Del Tacca, M, Danesi, R
Publicado 2005

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

por Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Publicado 2008

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

por Allegrini, G, Falcone, A, Fioravanti, A, Barletta, M T, Orlandi, P, Loupakis, F, Cerri, E, Masi, G, Di Paolo, A, Kerbel, R S, Danesi, R, Del Tacca, M, Bocci, G
Publicado 2008

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

por Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Publicado 2013

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

por Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Publicado 2011